Teaching Lariboisière Hospital
Paris, 75010, France
NCT Number: NCT00392639
According to international guidelines, mild therapeutic hypothermia is recommended for resuscitated patients after cardiac arrest due to ventricular fibrillation. Whether external or internal cooling is superior in terms of prognosis or security remains unknown. The aim of this study is to evaluate in a randomized trial the clinical and economical interests of the endovascular cooling versus the conventional external cooling for the management of hypothermia after cardiac arrest.
Looking for future studies?
Notify Me18 year–79 year
All sexes
Interventional
Phase 4
Paris, 75010, France
According to international guidelines, mild therapeutic hypothermia is recommended for resuscitated patients after experiencing cardiac arrest from cardiac origin: "unconscious adult patients with spontaneous circulation after cardiac arrest should be cooled to 32-34°C for 12-24 hours when the initial rhythm was ventricular fibrillation" or pulseless ventricular tachycardia. "Such cooling may also be beneficial for other rhythm or in-hospital cardiac arrest".
"External or internal cooling techniques can be used to initiate cooling within minutes to hours". The two main randomized and positive studies dealing with the efficiency of hypothermia after cardiac arrest have used external cooling systems. However, several animal studies documented the importance of initiating hypothermia as soon as possible after cardiac arrest. Intravascular cooling enables more rapid induction of hypothermia compared with external cooling method after brain injury. Although several human studies have also documented that intravascular cooling provides more precise control of core temperature than external methods and although an endovascular method has been used safely in pilot studies in those experiencing hypothermia after cardiac arrest, the superiority of such a cooling on the prognosis after cardiac arrest remains unknown, as well as its cost efficiency.
The aim of this study is to evaluate in a randomized trial the potential clinical and economical interests of the endovascular cooling versus the conventional external cooling for the management of cardiac arrest from cardiac origin. With a clinical primary endpoint (survival without major neurological sequels), this study will also focus on important secondary endpoints, as the burden of nurse work and the economical costs induced by these 2 different methods of cooling.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Comparison of 2 cooling procedures
Time frame: 28 days
Time frame: at 28 days
Time frame: at 28 days
Time frame: at 28 days
Time frame: at 28 days
Time frame: at 28 days
Time frame: at 28 days
Time frame: at 28 days
Time frame: at 28 days
Time frame: at 28 days
Time frame: at 28 days
Time frame: at 28 days
Time frame: at 28 days
Time frame: at 28 days and 90 days
Assistance Publique - Hôpitaux de Paris
Other
Clinical Interest of Endovascular Cooling in the Management of Cardiac Arrest: Impact on Mortality in a Randomized Medico-economical Trial (the ICEREA Study)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02555254
Body Temperature Changes, Cardiac Arrest
La Roche-sur-Yon, France
View Trial DetailsNCT03743584
Body Temperature Changes, Cardiovascular Diseases
Oslo, Norway
View Trial DetailsNCT02733146
Body Temperature Changes, Brain Diseases
Aarhus, Aarhus N, Denmark
View Trial DetailsNCT02179021
Body Temperature Changes, Cardiovascular Diseases
Aarhus N, Denmark
View Trial Details